Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | MVD | P53602 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | EYA2 | O00167 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8378681 | 0.90 | KMT2A (0.54) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL22061 | 0.82 | TDP1 (0.47) | TSHRHSD17B10MVDKDM6BKDM5C | |
| SCHEMBL11177575 | 0.81 | MGAM (0.50) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL18229249 | 0.79 | TDP1 (0.45) | TSHRHSD17B10MVDKDM6BKDM5C | |
| SCHEMBL6323180 | 0.79 | TDP1 (0.45) | TSHRHSD17B10MVDKDM6BKDM5C | |
| SCHEMBL28410047 | 0.79 | TDP1 (0.45) | TSHRHSD17B10MVDKDM6BKDM5C | |
| SCHEMBL6550670 | 0.79 | TDP1 (0.45) | TSHRHSD17B10MVDKDM6BKDM5C | |
| SCHEMBL6518392 | 0.79 | TDP1 (0.45) | TSHRHSD17B10MVDKDM6BKDM5C | |
| SCHEMBL28873500 | 0.79 | TDP1 (0.45) | KMT2ATSHRHSD17B10MVDKDM6B | |
| SCHEMBL692962 | 0.79 | TDP1 (0.45) | TSHRHSD17B10MVDKDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230278-A1 | METHOD FOR RECOVERING LITHIUM FROM LITHIUM PRECIPITATION MOTHER LIQUOR | Sunresin New Materials Co. Ltd., Xi'an (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3038200-B1 | ELECTROLYTE AND LITHIUM ION SECONDARY BATTERY | SEKISUI CHEMICAL CO LTD (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-20180198160-A1 | ELECTROLYTE SOLUTION AND LITHIUM ION SECONDARY BATTERY | SEKISUI CHEMICAL CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3346539-A1 | ELECTROLYTE SOLUTION AND LITHIUM ION SECONDARY BATTERY | Sekisui Chemical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9812735-B2 | Lithium ion secondary battery | SEKISUI CHEMICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| US-9728810-B2 | Electrolyte and lithium ion secondary battery | SEKISUI CHEMICAL CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| CN-105789688-A | Electrolyte and lithium ion secondary battery | 积水化学工业株式会社 | 2016-07-20 | — | — | CN | disclosed |
| EP-3038200-A1 | ELECTROLYTE AND LITHIUM ION SECONDARY BATTERY | Sekisui Chemical Co., Ltd. (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20160028119-A1 | LITHIUM ION SECONDARY BATTERY | SEKISUI CHEMICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160013516-A1 | ELECTROLYTE AND LITHIUM ION SECONDARY BATTERY | SEKISUI CHEMICAL CO., LTD. (JP) | 2016-01-14 | — | — | US | disclosed |
| CN-105074995-A | Electrolyte solution and lithium ion secondary battery | SEKISUI CHEMICAL CO LTD | 2015-11-18 | — | — | CN | disclosed |
| US-9108981-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2181103-B1 | SYSTEM FOR CONTROLLING THE REACTIVITY OF BORONIC ACIDS | UNIV ILLINOIS (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-26 | — | — | US | disclosed |
| US-8901115-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| US-20120114557-A1 | Methods for Collagen Imaging | Collagen Medical, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120027859-A1 | Biodegradable Proline-Based Polymers | MEDIVAS, LLC | 2012-02-02 | — | — | US | disclosed |
| EP-0194972-B1 | NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1992-07-29 | — | — | EP | disclosed |
| EP-0194972-A2 | Novel cyclosporins | SANDOZ AG (CH) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114557-A1 | Methods for Collagen Imaging | COL14A1, COL2A1, COL1A1 | KMT2A 4757/4885MEN1 1017/4885TSHR 3748/4885 |
| US-20120027859-A1 | Biodegradable Proline-Based Polymers | EPRS1, PRAP1, NPEPPS | KMT2A 2502/4885MEN1 4399/4885TSHR 4827/4885 |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | KMT2A 2170/4885MEN1 151/4885TSHR 3059/4885 |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | KMT2A 2170/4885MEN1 151/4885TSHR 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.